Literature DB >> 18448865

Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.

Justin C Earp1, Debra C Dubois, Diana S Molano, Nancy A Pyszczynski, Craig E Keller, Richard R Almon, William J Jusko.   

Abstract

A mechanism-based model was developed to describe the time course of arthritis progression in the rat. Arthritis was induced in male Lewis rats with type II porcine collagen into the base of the tail. Disease progression was monitored by paw swelling, bone mineral density (BMD), body weights, plasma corticosterone (CST) concentrations, and tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and glucocorticoid receptor (GR) mRNA expression in paw tissue. Bone mineral density was determined by PIXImus II dual energy X-ray densitometry. Plasma CST was assayed by high-performance liquid chromatography. Cytokine and GR mRNA were determined by quantitative real-time polymerase chain reaction. Disease progression models were constructed from transduction and indirect response models and applied using S-ADAPT software. A delay in the onset of increased paw TNF-alpha and IL-6 mRNA concentrations was successfully characterized by simple transduction. This rise was closely followed by an up-regulation of GR mRNA and CST concentrations. Paw swelling and body weight responses peaked approximately 21 days after induction, whereas bone mineral density changes were greatest at 23 days after induction. After peak response, the time course in IL-1beta, IL-6 mRNA, and paw edema slowly declined toward a disease steady state. Model parameters indicate TNF-alpha and IL-1beta mRNA most significantly induce paw edema, whereas IL-6 mRNA exerted the most influence on BMD. The model for bone mineral density captures rates of turnover of cancellous and cortical bone and the fraction of each in the different regions analyzed. This small systems model integrates and quantitates multiple factors contributing to arthritis in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448865      PMCID: PMC2574807          DOI: 10.1124/jpet.108.137372

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.

Authors:  Anasuya Hazra; Nancy A Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

3.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

4.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

5.  Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Authors:  Y N Sun; D C DuBois; R R Almon; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

6.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

Authors:  Goonaseelan Pillai; Ronald Gieschke; Timothy Goggin; Philippe Jacqmin; Ralph C Schimmer; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

7.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

8.  NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION.

Authors:  Ulf H. Lerner
Journal:  Crit Rev Oral Biol Med       Date:  2004-01-01

9.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors:  N H Holford; K E Peace
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats.

Authors:  Rohini Ramakrishnan; Debra C DuBois; Richard R Almon; Nancy A Pyszczynski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

View more
  35 in total

Review 1.  Network-based approaches in drug discovery and early development.

Authors:  J M Harrold; M Ramanathan; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2013-09-11       Impact factor: 6.875

2.  Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

Authors:  Dongyang Liu; Hoi-Kei Lon; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-16       Impact factor: 2.745

3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats.

Authors:  Yuancheng Chen; Yanguang Cao; Jia Zhou; Xiaoquan Liu
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

4.  Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.

Authors:  Jurgen Bernd Bulitta; Ayhan Bingölbali; Beom Soo Shin; Cornelia Barbara Landersdorfer
Journal:  AAPS J       Date:  2011-03-03       Impact factor: 4.009

5.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

6.  Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2015-04-01       Impact factor: 3.922

Review 7.  Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.

Authors:  Jane P F Bai; Justin C Earp; Venkateswaran C Pillai
Journal:  AAPS J       Date:  2019-06-03       Impact factor: 4.009

Review 8.  Pharmacokinetic/pharmacodynamic modeling in inflammation.

Authors:  Hoi-Kei Lon; Dongyang Liu; William J Jusko
Journal:  Crit Rev Biomed Eng       Date:  2012

9.  Application of a mechanism-based disease systems model for osteoporosis to clinical data.

Authors:  Teun M Post; Stephan Schmidt; Lambertus A Peletier; Rik de Greef; Thomas Kerbusch; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-12       Impact factor: 2.745

10.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.